Search research articles
Contact Us
Filters
Showing results (491-500 of 643) with videos related to
Page
of 65
Sort By:
The Lancet. Oncology
|
May 6, 2024
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Bob T Li, Funda Meric-Bernstam, Aditya Bardia, et al.
Cancer Discovery
|
December 3, 2017
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H Strickler, Jonathan M Loree, Leanne G Ahronian, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Nature Communications
|
January 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction
Linjie Luo, Yan Wang, Tuyen Bui, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2024
Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer
Luisa E Jacomina, David M Swanson, Melissa P Mitchell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Cancer
|
November 23, 2017
Physician interpretation of genomic test results and treatment selection
Lauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Cancer Discovery
|
October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S Hong, Van K Morris, Badi El Osta, et al.
Page
of 65
Search research articles
Search
Showing results (491-500 of 643) with videos related to
Sort By:
Page
of 65
The Lancet. Oncology
|
May 6, 2024
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Bob T Li, Funda Meric-Bernstam, Aditya Bardia, et al.
Cancer Discovery
|
December 3, 2017
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H Strickler, Jonathan M Loree, Leanne G Ahronian, et al.
Oncotarget
|
May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I program
Genevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget
|
April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
Denis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Nature Communications
|
January 22, 2026
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction
Linjie Luo, Yan Wang, Tuyen Bui, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2024
Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer
Luisa E Jacomina, David M Swanson, Melissa P Mitchell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic
Denis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Cancer
|
November 23, 2017
Physician interpretation of genomic test results and treatment selection
Lauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Cancer Discovery
|
October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S Hong, Van K Morris, Badi El Osta, et al.
Page
of 65